07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor coactivator 3 (NCOA3; SRC3; AIB1)

Cancer INDICATION: Breast cancer; cancer In vitro testing, cell culture and mouse studies identified a small molecule inhibitor of NCOA3 that could help treat triple-negative breast cancer (TNBC). Screening of a small molecule library, in...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor coactivator 1 (NCOA1; SRC1); NCOA2 (SRC2); NCOA3 (SRC3; AIB1)

Cancer INDICATION: Cancer In vitro and mouse studies suggest co-stimulating NCOA1 , NCOA2 and NCOA3 could help treat cancer. In multiple human cancer cell lines, a small molecule research compound that stimulated NCOA1, NCOA2 and...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

National Human Genome Research Institute other research news

NIH researchers and collaborators published in Science their characterization of a gene that is a possible player in breast cancer. The AIB1 gene is over-expressed in breast and ovarian cancers (four of five cell lines...
08:00 , Nov 6, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes; obesity Nuclear receptor coactivator 3 (NCOA3; SRC-3); peroxisome proliferator-activated receptor-g, coactivator 1a (PGC-1a) Studies in mice suggest that antagonizing...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Company News

Baylor College of Medicine other research news

Researchers published in the Journal of the National Cancer Institute that high AIB1 (SRC-3) expression in breast cancer patients not receiving tamoxifen adjuvant therapy was associated with a better prognosis and a longer disease-free survival...
08:00 , Apr 1, 2002 |  BC Week In Review  |  Company News

Harvard Medical School other research news

Researchers published in Science evidence that the differential activity of the SERMs tamoxifen and raloxifene in breast and endometrial tissue is related to altered recruitment of transcriptional activators. Tamoxifen and raloxifene both failed to induce...